�UroToday.com - In the September, 2008 issue of the Journal of Urology, Dr. Hiroyoshi Suzuki and Japanese collaborators reported that following upper limit androgen bar (MAB) for prostate cancer (CaP), the use of alternative nonsteroid antiandrogens is effective for treating relapsed disease. A total of 232 CaP patients treated with MAB and disease progression made up the study cohort. Upon disease relapse they were toughened with an alternative antiandrogen.
For first-line therapy, 39 men received MAB victimisation flutamide and 193 were treated with MAB victimisation bicalutamide. At the time of CaP progression, the first line antiandrogen was stopped and patients assessed for antiandrogens withdrawal syndrome. Second bank line antiandrogens were then started. Testosterone was confirmed to be in the castrate level. Standard disease response criteria were used.
All patients achieved castrate levels of testosterone. Mean patient age was 71.5 years and PSA earlier treatment was 1,047ng/ml. Of the 193 hands initially treated with bicalutamide, 143 (74%) achieved a complete reaction (CR) and all attained a CR or partial response (RP). Of the 39 flutamide treated patients, 32 (82%) achieved a CR and all attained a CR or PR. The duration of the first
